{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:10:15Z","timestamp":1787451015522,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejca.2017.12.007","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T12:30:25Z","timestamp":1516365025000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study"],"prefix":"10.1016","volume":"91","author":[{"given":"Sara","family":"Valpione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan J.","family":"Mooradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnaMaria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"de Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2164","authenticated-orcid":false,"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.12.007_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4260","key":"10.1016\/j.ejca.2017.12.007_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"7436","key":"10.1016\/j.ejca.2017.12.007_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.007_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"issue":"7547","key":"10.1016\/j.ejca.2017.12.007_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejca.2017.12.007_bib6","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"Santini","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2017.12.007_bib7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/annonc\/mdn423","article-title":"Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"5\u20136","key":"10.1016\/j.ejca.2017.12.007_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000326488","article-title":"Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib","volume":"79","author":"Asahina","year":"2010","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ejca.2017.12.007_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1245\/s10434-011-2120-6","article-title":"Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib","volume":"19","author":"Italiano","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6 Pt. B","key":"10.1016\/j.ejca.2017.12.007_bib10","doi-asserted-by":"crossref","first-page":"E228","DOI":"10.1111\/j.1464-410X.2011.10905.x","article-title":"Sorafenib rechallenge in patients with metastatic renal cell carcinoma","volume":"110","author":"Nozawa","year":"2012","journal-title":"BJU Int"},{"issue":"23","key":"10.1016\/j.ejca.2017.12.007_bib11","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1002\/cncr.25583","article-title":"Sunitinib rechallenge in metastatic renal cell carcinoma patients","volume":"116","author":"Zama","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.12.007_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085004","article-title":"Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma","volume":"9","author":"Menzies","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ejca.2017.12.007_bib13","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.007_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","article-title":"Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor","volume":"22","author":"Seghers","year":"2012","journal-title":"Melanoma Res"},{"issue":"20","key":"10.1016\/j.ejca.2017.12.007_bib15","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-13-0661","article-title":"Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression","volume":"19","author":"Romano","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.007_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CMR.0000000000000196","article-title":"BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma","volume":"25","author":"Roux","year":"2015","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.007_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1758834014548187","article-title":"Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series","volume":"6","author":"Dooley","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.007_bib18","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/bjd.15345","article-title":"BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients","volume":"177","author":"Vanhaecke","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.007_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/CMR.0000000000000350","article-title":"BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response","volume":"27","author":"Desvignes","year":"2017","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.007_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CMR.0000000000000320","article-title":"Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination","volume":"27","author":"Rogiers","year":"2017","journal-title":"Melanoma Res"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.007_bib21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/jdv.14268","article-title":"Successful retreatment with combined BRAF\/MEK inhibition in metastatic BRAFV600-mutated melanoma","volume":"31","author":"Amann","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.007_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9839","key":"10.1016\/j.ejca.2017.12.007_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.007_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.12.007_bib25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.12.007_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.007_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejca.2017.12.007_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ejca.2017.12.007_bib29","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7326","key":"10.1016\/j.ejca.2017.12.007_bib30","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/468902a","article-title":"Drug discovery: how melanomas bypass new therapy","volume":"468","author":"Solit","year":"2010","journal-title":"Nature"},{"issue":"7494","key":"10.1016\/j.ejca.2017.12.007_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ejca.2017.12.007_bib32","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-14-1174","article-title":"Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy","volume":"74","author":"Kemper","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.12.007_bib33","doi-asserted-by":"crossref","first-page":"30405","DOI":"10.1038\/srep30405","article-title":"Melanoma dormancy in a mouse model is linked to GILZ\/FOXO3A-dependent quiescence of disseminated stem-like cells","volume":"6","author":"Touil","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.007_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.stem.2010.03.008","article-title":"Cycling toward elimination of leukemic stem cells","volume":"6","author":"Goff","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.ejca.2017.12.007_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nm.3863","article-title":"Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR","volume":"21","author":"Vizoso","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejca.2017.12.007_bib36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.12.007_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2015.10.062","article-title":"Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours","volume":"54","author":"Valpione","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.007_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ejca.2017.12.007_bib39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","article-title":"Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis","volume":"10","author":"Gold","year":"2009","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2017.12.007_bib40","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ejca.2015.06.130","article-title":"Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab","volume":"51","author":"Valpione","year":"2015","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.007_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2018.02.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T13:22:16Z","timestamp":1535116936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917314867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":41,"alternative-id":["S0959804917314867"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.007","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2018.02.001","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}